Abstract:Introduction: Arylboronates afford rapid aqueous F-18-labeling via the creation of a highly polar F-18-aryltrifluoroborate anion (F-18-ArBF3-).Hypothesis: Radiosynthesis of an F-18-ArBF3- can be successfully applied to a clinically relevant peptide. To test this hypothesis we labeled dimeric-cylcoRGD, [c(RGDfK)](2)E because a) it is molecularly complex and provides a challenging substrate to test the application of this technique and b) [c(RGDfK)](2)E has already been labeled via several F-18-labeling methods which provide for a preliminary comparison.Goal: To validate this labeling method in the context of a complex and clinically relevant tracer to show tumor-specific uptake ex vivo with representative PET images in vivo.Methods: An arylborimidine was conjugated to [c(RGDfK)](2)E to give the precursor [c(RGDfK)](2)E-ArB(dan) which was aliquoted and stored at-20 degrees C. Aliquots of 10 or 25 nmol containing only micrograms of precursor were labeled using relatively low levels of F-18-activity. Following purification eight mice (pre-blocked/unblocked) with U87M xenograft tumors were injected with [c(RGDfK)(2)E-F-18-ArBF3- (n = 4) for ex vivo tissue dissection. Two sets of mice (pre-blocked/unblocked) were also imaged with PET-CT (n = 2).Results: The [c(RGDfK)](2)E-ArB(dan) is converted within 15 min to [c(RGDfK)](2)E-F-18-ArBF3- in isolated radiochemical yields of similar to 10% (n = 3) at a minimum effective specific activity of 0.3 Ci/mu mol. Biodistribution shows rapid clearance to the bladder via the kidney resulting in high tumor-to-blood and tumor-to-muscle ratios of >9 and >6 respectively while pre-blocking with [c(RGDfK)](2)E showed high tumor specificity. PET imaging showed good contrast between tumor and non-target tissues confirming the biodistribution data.Conclusion: An arylborimidine-RGD peptide is rapidly F-18-labeled in one step in good yield at useful specific activity. Biodistribution studies with blocking controls show tumor specificity which is corroborated by PET images.Advances in Knowledge and Implications for patient Care: Despite many antecedent examples of labeled RGD tracers this work is the first to show direct aqueous labeling of bisRGD with an F-18-ArBF3-. Labeling occurs in near record rapidity (45 min) at useful effective specific activities and competitive yields for high contrast tumor specific images. As bisRGD has been imaged in humans with several prosthetics this work suggests potential clinical applications of tracers appended with an F-18-ArBF3- More generally the ability to label a molecularly complex tracer suggests that this method could be useful to label many other peptides. Furthermore these results portend the development of kits that use only microgram quantities of lyophilized precursor for on demand labeling. The ability to perform one-step aqueous labeling in under an hour to provide tracers with high T:NT ratios has important implications for developing radiotracers for use in fundamental research and in preclinical tracer studies. (C) 2013 Elsevier Inc. All rights reserved.

First Experience of 18F-Alfatide in Lung Cancer Patients Using a New Lyophilized Kit for Rapid Radiofluorination

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging

Preclinical evaluation and pilot clinical study of [18F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

Kit-like 18F-labeling of RGD-19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging.

18F-Alfatide II Automated Preparation Based on 18F-Minireactor and Micropet/ct Imaging in Tumor

Preclinical evaluation and first-in-human study of [18F]AlF-FAP-NUR for PET imaging cancer-associated fibroblasts

Diagnostic Value of a Novel RGD-peptide Based Tracer 18F-Alfatide II for Breast Cancer

18F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study

The Feasibility Of F-18-Alf-Nota-Prgd2 Pet/Ct For Monitoring Early Response Of Endostar Antiangiogenic Therapy In Human Nasopharyngeal Carcinoma Xenograft Model Compared With F-18-Fdg

A Pilot Study Of F-18-Alfatide Pet/Ct Imaging For Detecting Lymph Node Metastases In Patients With Non-Small Cell Lung Cancer

Single Step 18F-Labeling of Dimeric Cyclorgd for Functional PET Imaging of Tumors in Mice.

Synthesis and preclinical evaluation of novel 18 F-labeled fibroblast activation protein tracers for positron emission tomography imaging of cancer-associated fibroblasts

18F-labeled tracers targeting fibroblast activation protein

Clinical Translational Evaluation of Al18F-NOTA-FAPI for Fibroblast Activation Protein Targeted Tumour Imaging

Radiolabeling of RGD peptide and preliminary biological evaluation in mice bearing U87MG tumors.

A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer

Synthesis and Preclinical Evaluation of [18F]AlF‐NOTA‐Asp2‐PEG2‐Folate as a Novel Folate‐Receptor‐Targeted Tracer for PET Imaging

Radiosynthesis and preclinical evaluation of [ 18 F]AlF-labeled HBED-CC-FAPI derivatives for imaging of cancer-associated fibroblasts

Biological evaluation of a novel stable peptide PET molecular probe [18F]AlF-NOTA-DVAP targeting to tumor cell surface GRP78